Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma

Keyphrases

• Antitumor Effect 100%
• Oral Tongue Squamous Cell Carcinoma (OTSCC) 100%
• Heat Shock Protein 90 Inhibitor 100%
• NVP-AUY922 100%
• AKT1 25%
• Heat Shock Protein 90 (Hsp90) 25%
• HSC-2 25%
• Induced Apoptosis 12%
• Hypoxia-inducible factor-1α (HIF-1α) 12%
• Vascular Endothelial Growth Factor 12%
• Squamous Cell Carcinoma (SqCC) 12%
• Therapeutic Approaches 12%
• Adenosine Triphosphate 12%
• Tumor Progression 12%
• Binding Site 12%
• ErbB2 12%
• Chaperone Proteins 12%
• Oral Squamous 12%
• Oncoprotein 12%
• Client Proteins 12%
• HSC-2 Cells 12%
• Antitumor Therapy 12%
• Novartis 12%
• Xenograft Model 12%
• Cleaved caspase-3 12%
• P-S6 12%
• Squamous Carcinoma Cells 12%
• Anti-tumor Response 12%
• Cellular Chaperone 12%

Medicine and Dentistry

• Mouth Squamous Cell Carcinoma 100%
• Hsp90 Inhibitor 100%
• Luminespib 100%
• In Vitro 25%
• Heat Shock Protein 90 25%
• Client 25%
• Programmed Cell Death 12%
• Vasculotropin 12%
• Hypoxia Inducible Factor 1 12%
• Upregulation 12%
• Tumor Progression 12%
• Xenograft 12%
• Chaperone 12%
• Squamous Cell Carcinoma Cell 12%
• Oncoprotein 12%
• Binding Site 12%
• Adenosine Triphosphate 12%
• Caspase 3 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Heat Shock Protein 90 Inhibitor 100%
• Mouth Squamous Cell Carcinoma 100%
• Luminespib 100%
• Heat Shock Protein 90 25%
• Vasculotropin 12%
• Hypoxia Inducible Factor 1 12%
• Binding Site 12%
• Tumor Growth 12%
• Chaperone 12%
• Squamous Cell Carcinoma 12%
• Oncoprotein 12%
• Caspase 3 12%
• Adenosine Triphosphate 12%